Mild Hyperbaric Chamber: What 1.3 ATA Actually Delivers

A mild hyperbaric chamber typically refers to a soft shell device operating at 1.3 ATA. The lowest pressure commonly used in commercial HBOT equipment. The term “mild” is accurate in a literal sense: these chambers produce modest pressure and modest oxygen elevation. Understanding the evidence behind this pressure level helps buyers calibrate expectations correctly.

Mild chambers are FDA-cleared Class II devices. But cleared only for acute mountain sickness. All other uses are off-label. This does not make them useless, but it sets the honest boundary for what the research supports.

What “Mild” Means in Hyperbaric Terms

At 1.3 ATA with ambient air (approximately 21% O₂), the partial pressure of oxygen in the lungs reaches roughly 0.27 ATA. Breathing supplemental oxygen by mask at sea level achieves approximately the same dissolved oxygen increase without any pressurization at all.¹ With a concentrator providing 90 to 95% O₂ via mask, the dose improves. But still falls far below the 1.5 ATA bacteriostatic threshold and far below the 2.0+ ATA required for any UHMS-approved indication.²

The Clinical Evidence at 1.3 ATA

Positive signals exist at mild pressures, but the evidence is limited to small studies without control groups. A 2011 study in 15 healthy volunteers found that sessions at 1.3 ATA with ambient air reduced oxidative stress markers by 11% and improved fatigue scores significantly. But included no comparison group.³ A 2018 study in 10 participants found the highest oxygen saturation at 1.3 ATA with supplemental O₂, but measured no clinical endpoints.⁴

The 2022 Harch systematic review on mTBI found mixed results for 1.3 ATA with ambient air. One positive study, one negative. By contrast, 1.5 ATA with 100% oxygen produced four positive RCTs meeting Level 1 evidence criteria. The review concluded: “Increased pressure within a narrow range appears to be the more important effect than increased oxygen, which is effective over a broad range.”⁵

Mild Chamber Advantages for Home Use

Despite the clinical limitations, mild chambers offer real advantages for home wellness users. They are portable and foldable, typically under 100 lbs. They require no oxygen supply infrastructure. Just a standard electrical outlet and an air compressor. Entry-level FDA-cleared models start at approximately $4,000 to $4,500 (Newtowne C4-27, Summit to Sea Shallow Dive).

For athletes, biohackers, and wellness users not targeting a specific diagnosed condition, mild chambers offer accessible hyperbaric exposure with a very favorable safety profile. A 2023 safety study of 175 patients at 1.45 ATA found a total adverse event rate of 7.1% per session with zero cases of objective barotrauma. Significantly lower than rates at 2.0+ ATA.⁶

FDA-Cleared Mild Chamber Brands

Only three brands hold FDA 510(k) clearance for mild/soft hyperbaric chambers: OxyHealth, Summit to Sea, and Newtowne Hyperbarics. All operate at 1.3 ATA maximum. For higher-pressure home chambers (1.5 ATA), OxyRevo and Zeugma offer CE-certified options. Not FDA-cleared. At higher prices.

For a full comparison of home chamber options at different pressure levels, see the home hyperbaric chamber buying guide. For understanding the difference between mild and clinical pressure, see the hard shell vs soft shell hyperbaric chamber comparison. For a step up in pressure, the 1.5 ATA hyperbaric chamber is the next option up.

FAQs

Is a mild hyperbaric chamber the same as clinical HBOT?
No. Clinical HBOT uses 2.0 to 3.0 ATA with 100% medical-grade oxygen. Mild chambers use 1.3 ATA with ambient air. The UHMS does not classify mild chamber sessions as HBOT.

What conditions is a mild chamber cleared for?
Acute mountain sickness only. All other uses. Recovery, brain health, inflammation. Are off-label.

Is 1.3 ATA safe for regular home use?
Yes. The safety profile at 1.3 ATA is favorable. The main risk is ear barotrauma from improper equalization. Adverse event rates are lower at 1.3 ATA than at any higher clinical pressure.

References

References

1. Burman F. Low-pressure fabric hyperbaric chambers. S Afr Med J. 2019;109(4). PMID: 31084683. https://doi.org/10.7196/SAMJ.2019.v109i4.13934
2. Sack RA et al. Transcutaneous oximetry in chronic ulcer patients at 1.4 vs 2.0 ATA. Undersea Hyperb Med. 2023. PMID: 38615347.
3. Kim S et al. Effect of mild-pressure hyperbaric therapy on fatigue and oxidative stress. Health. 2011;3(7). https://doi.org/10.4236/HEALTH.2011.37071
4. Ke G et al. Assessment of oxygen saturation levels during mild hyperbaric chamber treatment. 2018. https://doi.org/10.15761/jcis.1000108
5. Harch P. Systematic review and dosage analysis: HBOT in mTBI PCS. Front Neurol. 2022. PMID: 35370898. https://doi.org/10.3389/fneur.2022.815076
6. Monge G et al. Safety of HBOT and evaluation of associated clinical parameters. Int J Transl Med Res Public Health. 2023. https://doi.org/10.21106/ijtmrph.430

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website